NHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial.
ADVERTISEMENT
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
NHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial.